Designed by Kelly Emrick, DHSc, PhD, MBA, BSRT(ARRT)R
Multi-Modality Imaging Center Development
An eight-phase methodology and interactive dashboard for researching, financing, licensing, and launching a free-standing MRI / CT / PET-CT facility in a suburban Midwest market.
The IMAGE-8 Development Framework
Eight sequential and overlapping phases that take a multi-modality imaging center from market concept to first scan, typically over 22–28 months. Each phase has gated deliverables, a critical path, and modality-specific considerations for MRI, CT, and PET/CT.
Market Discovery
- Service-area population
- Imaging utilization rates
- Competitor mapping (DIC, RAYUS, hospital-owned)
- Referrer density study
Modality Strategy
- MRI: 3T vs 1.5T vs Open
- CT: 64 vs 128 vs 256 slice
- PET/CT: digital TOF, theranostics
- Vendor selection & lead times
Site Selection
- Zoning & medical use approval
- Vibration spec for MRI
- Shielding for CT & PET
- Crane access for magnet install
Capital Formation
- Equipment financing
- Build-out construction loan
- Working capital reserve
- Investor / debt blend
Regulatory Pathway
- ACR accreditation (all)
- NRC / Agreement State (PET)
- CMS 855B + IDTF enrollment
- Authorized User & RSO
Construction & Install
- Tenant improvement build
- RF cage + magnet drop
- Hot lab + dose calibrator
- PACS / RIS integration
Workforce & Workflow
- Tech / NM-tech hiring
- Intake & scheduling design
- Protocol library
- RSO program & safety drills
Launch & Optimize
- Soft launch & ramp
- 5-Pillar KPI tracking
- Referrer feedback loops
- Continuous improvement
The Five Performance Pillars
The same framework that governs operations after launch must shape every decision before launch. Each pillar maps to specific dashboards inside this tool.
| Pillar | Pre-Launch Discipline | Post-Launch KPI |
|---|---|---|
| Operational | Workflow design, intake/scheduling architecture | Order-to-scan TAT, first-pass screen rate |
| Financial Scalability | Pro forma, payer mix modeling | Revenue/scan, denial rate, A/R days |
| Capacity Utilization | Modality sizing vs demand | Schedule fill rate, no-show rate |
| Imaging Economics | Contract analysis, radiopharm strategy | Contribution margin/exam, denial appeal win-rate |
| Sustainable Profitability | 5-year EBITDA pathway, reserve planning | EBITDA margin, cash days on hand |
What Makes Multi-Modality Different
Adding CT and especially PET/CT to a single-modality center introduces complexity that single-modality operators routinely underestimate. Three differences matter most:
- Radioactive materials license. PET requires an NRC or Agreement State medical use license, an Authorized User (AU) physician, a Radiation Safety Officer (RSO), a hot lab, and a documented dose-administration program. None of this is required for MRI or diagnostic CT.
- Cyclotron-dependent supply chain. F-18 FDG has a 109.7-minute half-life. Delivery distance from a regional cyclotron determines whether PET is viable at all.
- Three different referral channels. MRI is orthopedic and neuro-heavy; CT is acute and cardiovascular; PET/CT is oncology-heavy. The referrer outreach plan, marketing collateral, and contract strategy diverge by modality.
Critical Path Dependencies
These items can singlehandedly delay launch by 3–6 months if not started early. Order matters.
| Dependency | Phase | Lead Time | Risk if Missed |
|---|---|---|---|
| 3T MRI order & magnet delivery | 2 | 9–14 months | Launch slip |
| NRC / Agreement State medical use license | 5 | 6–12 months | No PET launch |
| Cyclotron supply contract (FDG) | 5 | 3–6 months | No PET launch |
| ACR accreditation cycle | 5 | 9–12 months | Many payers won’t credential |
| Authorized User (AU) physician contract | 5 | 3–6 months | No PET billing |
| CMS 855B + IDTF site survey | 5 | 6–9 months | No Medicare billing |
| Commercial payer credentialing | 5 | 4–9 months | Cash-only at launch |
| Tenant improvement / shielding build | 6 | 4–7 months | Launch slip |
Service Area Demand Modeler
Estimate addressable annual exam volume for each modality based on service-area population, peer-reviewed utilization benchmarks, and capturable market share. This is the foundation for every downstream decision.
Service Area Inputs
Utilization Benchmarks (per 1,000 population, annual)
Adjust if your market intelligence supports different rates. National averages derived from CMS, AHRQ, and Radiological Society benchmarks.
Estimated Addressable Volume
Suburban Midwest Market Notes
- Demographics favor multi-modality. Suburban Midwest markets (Kansas City, Indianapolis, Columbus, Minneapolis suburbs) have stable populations with growing 55+ cohorts — the high-utilization age band for PET, MRI knee/spine, and CT cardiac.
- Lower competitive intensity than coastal markets. Most Midwest suburbs have 2–4 outpatient imaging operators per 200K population vs 6–10 on coasts.
- Hospital-owned share is high. Free-standing share of outpatient imaging is 30–40% in most Midwest markets vs 55%+ in mature coastal markets — meaning more room for share capture.
- Self-pay / direct-to-consumer demand is rising. Cash-pay MRI screening and proactive PET-based longevity imaging are growing categories.
- Workers’ comp and personal-injury referrals are durable secondary channels.
Competitive Benchmark Worksheet
Map every imaging operator within a 15-mile radius. Capture this data during Phase 1 windshield surveys and online research.
| Operator Type | Typical # in PSA | Modality Risk |
|---|---|---|
| Hospital outpatient dept | 2–4 | All modalities; price & convenience exposure |
| National chain (RAYUS, SimonMed) | 1–2 | MRI/CT; PET often absent |
| Radiologist-owned IDTF | 1–3 | MRI/CT; PET sometimes |
| Orthopedic in-office MRI | 2–6 | MRI extremity only |
| Oncology practice PET/CT | 0–2 | PET only; in-network captive |
| Cardiology PET/SPECT | 0–2 | Cardiac PET only |
Capacity & Technology Calculator
Size each modality to expected demand. Capacity is a function of operating hours, exam duration, target utilization, and shift design. Set capacity 15–20% above Year-1 expected volume to allow for growth without immediate equipment additions.
3T MRI Capacity
64-Slice CT Capacity
PET/CT Capacity
Capacity vs Demand Reconciliation
Compare capacity sized here against demand from the Market tab. Year-1 should target 50–65% utilization; mature operations 70–85%.
Technology Decision Matrix
| Decision | Option A | Option B | Recommendation |
|---|---|---|---|
| MRI field strength | 1.5T | 3T | 3T for ortho/neuro market; 1.5T for high-claustrophobia / pediatric mix |
| MRI bore | Standard 60cm | Wide-bore 70cm | Wide-bore — improves bariatric and claustrophobic patient throughput |
| CT slice count | 64-slice | 128-slice | 64 sufficient for general; 128 needed for CCTA & advanced cardiac |
| PET/CT detector | Analog | Digital (TOF) | Digital — better SUV quantification, shorter exam, theranostics-ready |
| PET/CT detector array | 16-slice CT | 64-slice CT | 64-slice CT — enables single-equipment cardiac PET/CTA |
Why PET/CT Schedules Differently
PET cannot operate on the same schedule logic as MRI or CT, for three reasons:
- FDG half-life dictates dose windows. F-18 FDG decays at 109.7 minutes. Cyclotron deliveries arrive in specific windows; patients must be injected and uptaken within those windows.
- Uptake time is fixed. Patients sit quietly for 45–60 minutes between injection and scan. This requires 2 quiet uptake rooms minimum to maintain throughput.
- Fasting and glucose protocols. Diabetic patients require glucose checks; scheduling must allow time for blood glucose remediation.
Weighted Site Scorecard
Score candidate sites against the criteria that matter for multi-modality imaging. Building specifications matter more than tenants often realize: MRI requires vibration isolation, CT and PET require radiation shielding, and the magnet must be physically delivered through a crane-accessible path.
Site A — Score Inputs (0–10)
Site B — Score Inputs (0–10)
Side-by-Side Comparison
Building Specification Checklist
Walk every candidate site with this list. A weak site discovered late costs 6–9 months of redesign.
| Spec | Modality | Threshold | Why It Matters |
|---|---|---|---|
| Ceiling height (slab to slab) | MRI | ≥ 11′ | Magnet height + cryogen ceiling clearance |
| Floor load capacity | MRI | ≥ 175 lbs/sf | 3T magnet weighs 11,000–14,000 lbs |
| Vibration (VC-D or better) | MRI | ≤ 25 µm/sec RMS | Vibration above threshold degrades image quality |
| Crane / removable wall access | MRI | Direct line | Magnet cannot navigate corners; require knock-out wall |
| External cryogen vent path | MRI | Roof access | Quench requires 8″ vent stack to exterior |
| Lead shielding | CT, PET | Per physicist calc | Wall thickness varies by adjacent occupancy |
| Hot lab (radiopharm prep) | PET | ~80 sq ft | Dose calibrator, L-shield, dose drawing |
| Patient uptake rooms | PET | 2+ quiet rooms | 45–60 min uptake per patient |
| HVAC for hot lab | PET | Negative pressure | Radiopharm safety per RAM license |
| Parking spaces / 1,000 sf | All | ≥ 5 / 1,000 | Imaging patients arrive ~15 min before exam |
| Loading dock or back access | PET | Required | Daily radiopharm courier delivery |
| Generator / UPS | All | 30 min minimum | Mid-scan power loss damages equipment |
Multi-Modality Pro Forma
A simplified Year-3 stabilized pro forma. PET radiopharmaceutical cost is modeled separately because of CMS pass-through reimbursement mechanics in the outpatient setting.
Annual Volume (Year 3)
Net Revenue per Scan
Operating Expenses (Annual)
Year-3 Stabilized P&L
Indicative Capital Stack
| Use of Funds | Range |
|---|---|
| 3T MRI (equipment + coils + install) | $1.8M – $2.4M |
| 64-slice CT (equipment + install) | $0.5M – $0.8M |
| Digital PET/CT (equipment + install) | $2.0M – $2.8M |
| RF cage, shielding, hot lab build | $0.4M – $0.7M |
| Tenant improvement (8,000–10,000 sf) | $1.8M – $3.0M |
| PACS / RIS / dose mgmt software | $0.15M – $0.30M |
| Pre-opening expenses (licensing, recruiting) | $0.25M – $0.45M |
| Working capital reserve (6 months) | $1.5M – $2.2M |
| Total project capitalization | $8.4M – $12.6M |
Why PET Reimbursement Modeling Is Different
In the Medicare outpatient setting (OPPS), PET/CT is reimbursed through an APC payment for the technical service and a separate pass-through payment for the radiopharmaceutical.
- Technical component (APC): The bundled scan payment covers the room, technologist, and CT portion. CPT 78815 (whole body PET/CT) maps to a high-weight APC.
- Radiopharm pass-through: HCPCS A9552 (FDG) bills separately at average sales price (ASP). The differential between acquisition cost and ASP-based payment is the radiopharm margin.
- IDTF setting differs. Free-standing IDTFs bill under the Physician Fee Schedule, not OPPS — and bundle radiopharm differently. This must be modeled for the specific enrollment.
Licensing & Accreditation Tracker
A multi-modality center requires three parallel regulatory tracks. PET/CT is the most demanding because it requires a radioactive materials license that does not apply to MRI or diagnostic CT. Track completion below.
Regulatory Checklist
0% complete · Click items to mark done
Authorized User (AU) Physician — PET
An AU is a physician named on the NRC / Agreement State license who is qualified to administer radiopharmaceuticals. For diagnostic PET, qualifications require:
- Board certification in nuclear medicine, OR
- 700 hours of training/experience including 200 hours of classroom + 500 hours of supervised work experience with radioactive materials, OR
- ABR-certified radiologist with documented nuclear medicine training
The AU is named on the license application and accepts personal regulatory responsibility for radiopharm administration practices at the facility. Replacing an AU requires a license amendment.
Radiation Safety Officer (RSO) — PET
The RSO is the individual responsible for the facility’s radiation safety program. Required qualifications include:
- Bachelor’s or higher in physical or biological science / engineering
- 200 hours of training in radiation safety topics
- One year of full-time radiation safety experience
- Documented training in regulatory requirements
A medical physicist consultant often fills this role in smaller centers under a contracted arrangement. The RSO must be named on the license, and license amendments are required for RSO changes.
Kansas-Specific Notes
- Kansas is an NRC state, not an Agreement State. Radioactive materials medical use licenses are issued by the U.S. NRC Region IV office. Application processing typically 6–9 months.
- Kansas Department of Health and Environment (KDHE) regulates X-ray (CT) facility registration and operator certification.
- No certificate of need (CON) for outpatient imaging in Kansas — a meaningful advantage vs CON states.
- Chiropractor referrals are legal for MRI and CT in Kansas under K.S.A. 65-2871(a). PET referrals from chiropractors are clinically uncommon but not prohibited.
Radiopharmaceutical Economics & Logistics
PET/CT viability is largely a question of radiopharmaceutical supply. FDG cyclotron proximity, dose timing, and pass-through reimbursement together determine whether PET makes economic sense at a given site.
FDG Decay & Dose Math
F-18 FDG has a physical half-life of 109.7 minutes. Each half-life that elapses between manufacture and patient administration cuts available activity in half. This determines viable cyclotron distance and dose ordering strategy.
Decay Curve
Radiopharm Margin Calculator
Tracer Landscape
| Tracer | Half-Life | Use |
|---|---|---|
| F-18 FDG | 109.7 min | Oncology, infection, cardiac viability |
| F-18 PSMA (Pylarify) | 109.7 min | Prostate cancer |
| F-18 Florbetapir | 109.7 min | Amyloid (Alzheimer’s) |
| F-18 NaF | 109.7 min | Bone imaging |
| Ga-68 DOTATATE | 68 min | Neuroendocrine tumors |
| Ga-68 PSMA | 68 min | Prostate cancer |
| Rb-82 | 76 sec | Cardiac perfusion (generator) |
| C-11 Choline | 20.4 min | Prostate cancer (on-site only) |
Theranostics Outlook
Therapeutic radiopharmaceuticals are the fastest-growing segment of nuclear medicine. Free-standing centers with PET infrastructure are positioned to add theranostics as a service line.
- Lu-177 PSMA-617 (Pluvicto): Prostate cancer; ~$42K per dose; 6 cycles typical
- Lu-177 DOTATATE (Lutathera): Neuroendocrine; ~$50K per dose; 4 cycles typical
- Ac-225 trials: Next-generation alpha-emitter therapies in Phase 2/3
Adding theranostics requires expanded license authorization, dedicated treatment room, and an Authorized User with therapy credentials. Reimbursement is via J-codes with high pass-through margins, but patient logistics (infusion, post-dose isolation) demand a different workflow.
Five-Pillar Performance Maturity
A self-assessment instrument mapping the five performance pillars to 25 specific capabilities. Use as a pre-launch readiness check, an early-operations diagnostic, or a board-level performance review. Score: 1 (not yet) to 5 (fully institutionalized).
Maturity Self-Assessment
Pillar Scorecard
Overall Maturity
Interpretation Guide
| Band | Range | Meaning | Recommended Next Action |
|---|---|---|---|
| Founding | 0–50% | Capabilities being established; reliance on individual heroics | Build standard work; document workflows; appoint accountable owners |
| Emerging | 51–70% | Capabilities exist but inconsistent across staff and shifts | Train to standard work; install measurement; close obvious variance gaps |
| Operating | 71–85% | Reliable execution; data-driven decision-making | Push toward integration across pillars; benchmark to top quartile |
| Mastered | 86–100% | Institutionalized excellence; durable to staff turnover | Become a teaching site; export discipline to acquired or expansion sites |